Expertise in
14
conditions

Dr. Cheryl A. Hull

Rogers, AR
Expertise in
14
conditions
Specialties:Dermatology
Accepting New Patients
Expertise in
14
conditions
OverviewInsuranceLocationsClinical Research

Overview

Cheryl Hull is a Dermatologist in Rogers, Arkansas. Dr. Hull is highly rated in 14 conditions, according to our data. Her top areas of expertise are Actinic Keratosis, Psoriasis, Warts, and Seborrheic Keratosis. Dr. Hull is currently accepting new patients.

Her clinical research consists of co-authoring 2 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in AR
Languages Spoken
English
Spanish
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Blue Cross Blue Shield
  •  HMO Partners
  •  Oscar
  •  Humana

Locations

HULL DERMATOLOGY P.A.
500 S 52nd St, Rogers, AR 72758
479-254-9662

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Enrollment Status: Completed
Publish Date: April 28, 2023
Intervention Type: Drug
Study Drug: LY3041658
Study Phase: Phase 2
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
A Phase II, Multicenter, Double-blind, Double-dummy, Placebo Controlled, Randomized Study to Evaluate the Efficacy and Safety of AUR101 in Patients With Moderate-to-Severe Psoriasis (INDUS-3)
Enrollment Status: Completed
Publish Date: December 13, 2022
Intervention Type: Drug
Study Drug: AUR101
Study Phase: Phase 2
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Drug, Biological
Study Phase: Phase 2
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne
Enrollment Status: Completed
Publish Date: April 27, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis
A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 mo of Age) With Mild to Moderate Plaque Psoriasis
Enrollment Status: Completed
Publish Date: February 18, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)
Enrollment Status: Completed
Publish Date: June 04, 2019
Intervention Type: Other, Biological
Study Phase: Phase 2
View 10 Less Clinical Trials

2 Total Publications

Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Post hoc pediatric subgroup analysis from a 44-week open-label extension study.
Journal: Pediatric dermatology
Published: December 05, 2019
Similar Doctors
Expertise in
13
conditions
Dr. Mark F. Naylor
Dermatology
Expertise in
13
conditions
Dr. Mark F. Naylor
Dermatology

Advanced Dermatology And Skin Cancer Center, LLC

1444 E Stearns St, Suite 11, 
Fayetteville, AR 
 (14.5 mi)
479-718-7546
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Naylor is a Dermatologist in Fayetteville, Arkansas. Dr. Naylor is highly rated in 13 conditions, according to our data. His top areas of expertise are Pompholyx Eczema, Basal Cell Skin Cancer, GAPO Syndrome, and Atopic Dermatitis. Dr. Naylor is currently accepting new patients.

Expertise in
18
conditions
Dr. Derek S. Towery
Dermatology
Expertise in
18
conditions
Dr. Derek S. Towery
Dermatology

Dermatology And Skin Cancer Specialists LLC

900 E 13th St, Suite 101, 
Grove, OK 
 (36.2 mi)
417-624-0440
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Derek Towery is a Dermatologist in Grove, Oklahoma. Dr. Towery is highly rated in 18 conditions, according to our data. His top areas of expertise are Seborrheic Keratosis, Actinic Keratosis, Warts, and Plaque Psoriasis. Dr. Towery is currently accepting new patients.

Expertise in
28
conditions
Dr. Douglas M. Leone
Dermatology
Expertise in
28
conditions
Dr. Douglas M. Leone
Dermatology

Dermatology And Mohs Surgery Skin Cancer Center

110 Business Park Dr, Suite C, 
Branson, MO 
 (59.6 mi)
417-336-0033
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Douglas Leone is a Dermatologist in Branson, Missouri. Dr. Leone is highly rated in 28 conditions, according to our data. His top areas of expertise are Neurocutaneous Melanosis, Giant Congenital Melanocytic Nevus, Familial Atypical Multiple Mole Melanoma Syndrome, and Giant Congenital Nevus. Dr. Leone is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile